- Company
- Hemlibra reduces risk of exercise-associated bleeding
- by Lee, Seok-Jun Jan 19, 2024 05:44am
- The research findings, which include data on the physical activities of patients treated with JW Pharmaceutical’s hemophilia A treatment ‘Hemlibra (emicizumab)’ and their safety profile, have been published in the International Journal of Hematology (Int J Hematol). Hemlibra is an innovative new drug that mimics the function of blood
- Company
- Keytruda's reimb for 6 indications will be reviewed
- by Eo, Yun-Ho Jan 19, 2024 05:44am
- The reimbursement challenge for Keytruda continues this year. Although no results have been made, the company seems to be on a steady course in applying for reimbursement. According to industry sources, 6 indications of MSD Korea’s PD-1 inhibitor immuno-oncology drug Keytruda (pembrolizumab) are expected to be submitted to the Health Ins
- Company
- AstraZeneca begins ERP and business unit restructuring
- by Son, Hyung-Min Jan 18, 2024 04:51pm
- AstraZeneca Korea has initiated an early retirement program following the withdrawal of the diabetes treatment Forxiga from the Korean market. The company has stated that it is in discussions with the government to minimize the impact of Forxiga’s withdrawal along with its business unit restructuring. According to the pharmaceutical industr
- Company
- Keytruda approved as 1st-line treatment for gastric cancer
- by Son, Hyung-Min Jan 18, 2024 04:46pm
- Keytruda, a cancer immunotherapy developed by MSD, has been approved as a first-line treatment for gastric cancer in Korea. Keytruda has emerged as a new first-line treatment option, thirteen years after Herceptin (ingredient: trastuzumab) received approval in 2010. On the 16th, MSD hosted a press conference at Lotte Hotel Seoul commenci
- Company
- MA manager files complaint on NHIS official's abuse of power
- by Eo, Yun-Ho Jan 18, 2024 06:07am
- A controversy has arisen over the abuse of power made by an official from the National Health Insurance Service’s Department of Pharmaceutical Benefits. According to industry sources, B, a market access (MA) manager at pharmaceutical company A, filed a civil complaint with the Anti-Corruption & Civil Rights Commission’s e-People page, a
- Company
- Orion bids KRW 548.5 bil to enter the pharma industry
- by Kim, Jin-Gu Jan 17, 2024 05:29am
- The Orion Group has become the largest shareholder of LegoChem Biosciences, a prime new drug developer. With the acquisition of LegoChem, Orion is expected to jump into the pharmaceutical bio-industry in earnest, breaking away from its previous passive activities such as signing a memorandum of understandings, making indirect investments
- Company
- KRPIA's new BOD is full of Korean members
- by Eo, Yun-Ho Jan 17, 2024 05:29am
- KRPIA has launched its new board of directors for the 2024 New Year. The Korean Research-based Pharmaceutical Industry Association (KRPIA) has recently announced its new board of directors (BOD). The new BOD stands out as it is primarily made up of Korean members. Among the 13 BOD members, which includes KRPIA chairman Dong-Wook O
- Company
- Whan In has exclusive distribution rights for Sanofi's Arava
- by Kim, Jin-Gu Jan 16, 2024 06:09am
- On the 10th, Whan In Pharm announced that the company signed an exclusive promotion and distribution agreement with Sanofi-Aventis for Arava Tablet, a rheumatoid arthritis treatment containing the active ingredient leflunomide, in Korea. Whan In Pharm is recognized for its business specialization in the central nervous system (CNS) fiel
- Company
- Gov't will reduce fines for companies that adopt CPs
- by Kang, Shin-Kook Jan 16, 2024 06:08am
- A revised Fair Trade Act that grants benefits, such as reduced penalty surcharges to companies that have adopted and excellently operated a Fair Trade Compliance Program (CP), will be enforced on June 21st this year. On the 15th, the Fair Trade Commission announced that it would prepare sub-statutes, including the Enforcement Decree and N
- Company
- Reimbursed drugs hit four-year low amid regulatory changes
- by Chon, Seung-Hyun Jan 16, 2024 06:08am
- The number of drugs on the health insurance reimbursement list has reached its lowest point in four and a half years. Due to pricing revisions for generic drugs and regulations related to joint development, the introduction of new drugs is significantly reduced. The number of approvals has decreased by more than 70% compared to the figures
